Maxim Analyst initiates Buy with 3$ US Target
Oncolytics initiated with a Buy at Maxim Maxim analyst Jason McCarthy initiated coverage of Oncolytics with a Buy rating and $3.00 price target. The analyst is positive on the company's development of pelareorep, pela, an intravenously administered oncolytic virus designed to treat various solid tumors which has shown safety and signals of efficacy in over 1,100 patients. The next key to unlocking pela's potential is with checkpoints, and given the company's $25M cash position on the balance sheet at the end of June, Oncolytics has the runway into the second half of 2023, McCarthy tells investors in a research note. -------------------------------------- Definitely too low but always nice to have more coverage and attracting a wider investor Audience.